New Huntington's Drug Shows Promise in Early Trials
The RNA-based therapy significantly reduced toxic protein levels in a small group of study participants.
Updated on Oct. 27, 2026 in Alzheimer’s
An RNA-based therapy, brezosiran, has shown potential in a Phase 1b clinical trial by significantly reducing levels of the toxic huntingtin protein linked to Huntington's disease. The experimental drug, which is delivered directly into the spinal canal, may eventually offer a new treatment path for patients.
Why it matters
Huntington's disease is currently a progressive, incurable condition caused by the buildup of mutant huntingtin protein in the brain. This therapy aims to stop that protein's production at the genetic level to potentially slow disease progression.
In a Phase 1b trial of 48 participants, the RNA-based therapy brezosiran achieved a mean mutant huntingtin protein reduction of 60% to 64% three months post-injection, compared to placebo. These findings are preliminary, and large-scale efficacy is currently unknown.
The players
Alnylam Pharmaceuticals
A biopharmaceutical company specializing in RNA interference therapies for genetic and rare diseases.
The details
Brezosiran works as an RNA-based intervention designed to intercept the genetic instructions that lead to the production of the toxic huntingtin protein. By silencing these instructions, the therapy seeks to limit the accumulation of the protein in the central nervous system. The drug is administered via an injection into the spinal canal to reach the brain effectively, with trial data indicating that nerve damage markers and brain inflammation remained stable during the study period.
Timeline
The Phase 1b clinical trial launched in late 2024.
Results were presented at a research congress held October 22-24, 2026.
A pivotal study is expected to begin in 2027.
Health Landscape
This development represents a significant step in the broader search for effective huntingtin-lowering treatments. It follows a series of historically difficult trials for other genetic approaches in this field.
While these results are promising, the study was preliminary and not yet a standard clinical treatment option. Patients interested in future clinical trial opportunities should consult with a neurologist who specializes in movement disorders.
The takeaway
The study suggests that targeting huntingtin protein production via RNA-based therapy may be a viable strategy for slowing Huntington's disease. Patients and families should track future updates on the 2027 pivotal study as a key milestone for potential treatment availability.
What happens next
Alnylam Pharmaceuticals plans to launch a pivotal, placebo-controlled clinical study for brezosiran in 2027.
Further reading
For more on emerging research into neurodegenerative conditions, visit our Alzheimer’s section.
Source note: This article includes information reported by Huntington's Disease News.
